{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:57:37Z","timestamp":1762955857905},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semarthrit.2018.01.013","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T22:54:47Z","timestamp":1517612087000},"page":"288-292","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial"],"prefix":"10.1016","volume":"48","author":[{"given":"Eli M.","family":"Miloslavsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank B.","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.01.013_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/keq351","article-title":"Mortality in Wegener\u2019s granulomatosis: a bimodal pattern","volume":"50","author":"Luqmani","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2015.07.009","article-title":"Improved survival in granulomatosis with polyangiitis: a general population-based study","volume":"45","author":"Wallace","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case\u2013control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib12","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semarthrit.2018.01.013_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib17","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.4. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published 2009."},{"key":"10.1016\/j.semarthrit.2018.01.013_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: a cohort study","volume":"34","author":"Martinez Del Pero","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib21","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener\u2019s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib23","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/MD.0000000000000229","article-title":"Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA)","volume":"93","author":"Henderson","year":"2014","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.semarthrit.2018.01.013_bib24","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.01.013_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217307333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T19:34:47Z","timestamp":1541446487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217307333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0049017217307333"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}